Cytori Therapeutics (CYTX) Misses Q4 EPS by 4c/Share

Cytori Therapeutics (NASDAQ: CYTX) reported Q4 EPS of ($0.10), $0.04 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $2.74 million.

For earnings history and earnings-related data on Cytori Therapeutics (CYTX) click here.

You May Also Be Interested In

• Sprinklr (CXM) Tops Q2 EPS by 1c, Offers Guidance
• National Health Investors (NHI) PT Lowered to $80 at Truist Securities
• MongoDB (MDB) Tops Q2 EPS by 29c, Beats on Revenue; Offers FY37 Guidance